Cargando…

Multimodal evaluation of the cerebrovascular reserve in Neurofibromatosis type 1 patients with Moyamoya syndrome

PURPOSE: Moyamoya syndrome (MMS) is a rare intracranial arterial vasculopathy which can occur in neurofibromatosis type 1 (NF1) disease, representing a cause of cerebrovascular reserve (CVR) impairment, possibly leading to ischemic stroke. Here, we evaluated noninvasive imaging techniques used to as...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Amico, Alessandra, Ugga, Lorenzo, Cocozza, Sirio, Giorgio, Sara Maria delle Acque, Cicala, Domenico, Santoro, Claudia, Melis, Daniela, Cinalli, Giuseppe, Brunetti, Arturo, Pappatà, Sabina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843564/
https://www.ncbi.nlm.nih.gov/pubmed/32651859
http://dx.doi.org/10.1007/s10072-020-04574-4
_version_ 1783644174416871424
author D’Amico, Alessandra
Ugga, Lorenzo
Cocozza, Sirio
Giorgio, Sara Maria delle Acque
Cicala, Domenico
Santoro, Claudia
Melis, Daniela
Cinalli, Giuseppe
Brunetti, Arturo
Pappatà, Sabina
author_facet D’Amico, Alessandra
Ugga, Lorenzo
Cocozza, Sirio
Giorgio, Sara Maria delle Acque
Cicala, Domenico
Santoro, Claudia
Melis, Daniela
Cinalli, Giuseppe
Brunetti, Arturo
Pappatà, Sabina
author_sort D’Amico, Alessandra
collection PubMed
description PURPOSE: Moyamoya syndrome (MMS) is a rare intracranial arterial vasculopathy which can occur in neurofibromatosis type 1 (NF1) disease, representing a cause of cerebrovascular reserve (CVR) impairment, possibly leading to ischemic stroke. Here, we evaluated noninvasive imaging techniques used to assess CVR in MMS patients, describing clinical and imaging findings in patients affected by MMS-NF1. METHODS: Following strict inclusion and exclusion criteria, in this retrospective observational study, we evaluated imaging data of nine consecutive MMS-NF1 patients (M/F = 5/4, mean age: 12.6 ± 4.0). Subjects underwent a multimodal evaluation of cerebral vascular status, including intracranial arterial MR Angiography (MRA), MRI perfusion with dynamic susceptibility contrast (DSC) technique, and 99mTc-hexamethylpropyleneamine oxime (HMPAO) SPECT. RESULTS: In 8 out 9 patients (88.8%, 6/8 symptomatic), time-to-peak maps were correlated with the involved cerebral hemisphere, while in 6 out 9 patients (66.6%, 5/6 symptomatic), mean transit time (MTT) maps showed correspondence with the affected cerebrovascular territories. Cerebral blood flow (CBF) calculated using DSC perfusion failed to detect the hypoperfused regions instead identified by SPECT-CBF in all patients, while MTT maps overlapped with SPECT-CBF data in all cases and time-to-peak maps in 60.0%. CONCLUSIONS: Although SPECT imaging still represents the gold standard for CBF assessment, our results suggest that data obtained using DSC perfusion technique, and in particular MTT maps, might be a very useful and noninvasive tool for evaluating hemodynamic status in MMS-NF1 patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10072-020-04574-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7843564
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-78435642021-02-04 Multimodal evaluation of the cerebrovascular reserve in Neurofibromatosis type 1 patients with Moyamoya syndrome D’Amico, Alessandra Ugga, Lorenzo Cocozza, Sirio Giorgio, Sara Maria delle Acque Cicala, Domenico Santoro, Claudia Melis, Daniela Cinalli, Giuseppe Brunetti, Arturo Pappatà, Sabina Neurol Sci Original Article PURPOSE: Moyamoya syndrome (MMS) is a rare intracranial arterial vasculopathy which can occur in neurofibromatosis type 1 (NF1) disease, representing a cause of cerebrovascular reserve (CVR) impairment, possibly leading to ischemic stroke. Here, we evaluated noninvasive imaging techniques used to assess CVR in MMS patients, describing clinical and imaging findings in patients affected by MMS-NF1. METHODS: Following strict inclusion and exclusion criteria, in this retrospective observational study, we evaluated imaging data of nine consecutive MMS-NF1 patients (M/F = 5/4, mean age: 12.6 ± 4.0). Subjects underwent a multimodal evaluation of cerebral vascular status, including intracranial arterial MR Angiography (MRA), MRI perfusion with dynamic susceptibility contrast (DSC) technique, and 99mTc-hexamethylpropyleneamine oxime (HMPAO) SPECT. RESULTS: In 8 out 9 patients (88.8%, 6/8 symptomatic), time-to-peak maps were correlated with the involved cerebral hemisphere, while in 6 out 9 patients (66.6%, 5/6 symptomatic), mean transit time (MTT) maps showed correspondence with the affected cerebrovascular territories. Cerebral blood flow (CBF) calculated using DSC perfusion failed to detect the hypoperfused regions instead identified by SPECT-CBF in all patients, while MTT maps overlapped with SPECT-CBF data in all cases and time-to-peak maps in 60.0%. CONCLUSIONS: Although SPECT imaging still represents the gold standard for CBF assessment, our results suggest that data obtained using DSC perfusion technique, and in particular MTT maps, might be a very useful and noninvasive tool for evaluating hemodynamic status in MMS-NF1 patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10072-020-04574-4) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-07-10 2021 /pmc/articles/PMC7843564/ /pubmed/32651859 http://dx.doi.org/10.1007/s10072-020-04574-4 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Article
D’Amico, Alessandra
Ugga, Lorenzo
Cocozza, Sirio
Giorgio, Sara Maria delle Acque
Cicala, Domenico
Santoro, Claudia
Melis, Daniela
Cinalli, Giuseppe
Brunetti, Arturo
Pappatà, Sabina
Multimodal evaluation of the cerebrovascular reserve in Neurofibromatosis type 1 patients with Moyamoya syndrome
title Multimodal evaluation of the cerebrovascular reserve in Neurofibromatosis type 1 patients with Moyamoya syndrome
title_full Multimodal evaluation of the cerebrovascular reserve in Neurofibromatosis type 1 patients with Moyamoya syndrome
title_fullStr Multimodal evaluation of the cerebrovascular reserve in Neurofibromatosis type 1 patients with Moyamoya syndrome
title_full_unstemmed Multimodal evaluation of the cerebrovascular reserve in Neurofibromatosis type 1 patients with Moyamoya syndrome
title_short Multimodal evaluation of the cerebrovascular reserve in Neurofibromatosis type 1 patients with Moyamoya syndrome
title_sort multimodal evaluation of the cerebrovascular reserve in neurofibromatosis type 1 patients with moyamoya syndrome
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843564/
https://www.ncbi.nlm.nih.gov/pubmed/32651859
http://dx.doi.org/10.1007/s10072-020-04574-4
work_keys_str_mv AT damicoalessandra multimodalevaluationofthecerebrovascularreserveinneurofibromatosistype1patientswithmoyamoyasyndrome
AT uggalorenzo multimodalevaluationofthecerebrovascularreserveinneurofibromatosistype1patientswithmoyamoyasyndrome
AT cocozzasirio multimodalevaluationofthecerebrovascularreserveinneurofibromatosistype1patientswithmoyamoyasyndrome
AT giorgiosaramariadelleacque multimodalevaluationofthecerebrovascularreserveinneurofibromatosistype1patientswithmoyamoyasyndrome
AT cicaladomenico multimodalevaluationofthecerebrovascularreserveinneurofibromatosistype1patientswithmoyamoyasyndrome
AT santoroclaudia multimodalevaluationofthecerebrovascularreserveinneurofibromatosistype1patientswithmoyamoyasyndrome
AT melisdaniela multimodalevaluationofthecerebrovascularreserveinneurofibromatosistype1patientswithmoyamoyasyndrome
AT cinalligiuseppe multimodalevaluationofthecerebrovascularreserveinneurofibromatosistype1patientswithmoyamoyasyndrome
AT brunettiarturo multimodalevaluationofthecerebrovascularreserveinneurofibromatosistype1patientswithmoyamoyasyndrome
AT pappatasabina multimodalevaluationofthecerebrovascularreserveinneurofibromatosistype1patientswithmoyamoyasyndrome